Author: John Pinching

Foundation’s test to be used in Oxford-led blood biomarker trial

First long-acting therapy with three-monthly dosing to target root cause of cardiac disease

First PD-1 inhibitor plus ADC regimens for cisplatin-ineligible patients

Five-year deal aims to support UK biomedical talent and drive collaboration across sectors

Positive topline results highlight potential new option for secondary stroke prevention